<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045382</url>
  </required_header>
  <id_info>
    <org_study_id>TJB0909</org_study_id>
    <nct_id>NCT01045382</nct_id>
  </id_info>
  <brief_title>MSC and HSC Coinfusion in Mismatched Minitransplants</brief_title>
  <official_title>Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims at evaluating the capacity of MSC to improve one-year overall&#xD;
      survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors&#xD;
      after non-myeloablative conditioning.&#xD;
&#xD;
      Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC)&#xD;
      in an immunodeficient mouse model. In addition, it has been shown that infusion of third&#xD;
      party MSC in HSC transplantation could be successfully used as treatment for grade II-IV&#xD;
      steroid-refractory acute graft versus host disease.&#xD;
&#xD;
      One hundred and twenty patients with HLA-mismatched donors will be included over 6 years at&#xD;
      multiple centers across Belgium through the transplant committee of the Belgian Hematological&#xD;
      Society. The conditioning regimen will consist of fludarabine and 2 Gy TBI, followed by the&#xD;
      infusion of donor HSC. Patients will be randomized 1/1 in double-blind fashion to receive or&#xD;
      not MSC (1.5-.3.0 x106/kg) from third-party (either haploidentical family members or&#xD;
      unrelated volunteer) donors on day 0. Postgrafting immunosuppression will combine tacrolimus&#xD;
      and MMF. Except for the collection, expansion and infusion of MSC, the clinical management of&#xD;
      the patient will not differ from that of routine NM-HCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment too slow&#xD;
  </why_stopped>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year overall survival in the 2 arms.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV and grade III-IV acute GVDH</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of absolute donor T cells after HCT in each arm</measure>
    <time_frame>28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of non-relapse mortality</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extensive chronic GVHD in each arm</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft rejection in each arm.</measure>
    <time_frame>365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality and timing of immunologic reconstitution in each arm.</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of MSC from donor origin in recipient marrow after HCT in patients given MSC</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with measurable disease at HCT who achieve a complete response in each arm.</measure>
    <time_frame>100, 365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of progression-free survival</measure>
    <time_frame>365 and 730 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphoblastic, Acute</condition>
  <condition>Leukemia, Myelocytic, Chronic</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Mensenchymal Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.&#xD;
Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.&#xD;
MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.&#xD;
Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal stem cell injection</description>
    <arm_group_label>Mensenchymal Stem Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic solution</intervention_name>
    <description>Isotonic solution injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Theoretical indication for a standard allo-transplant, but not feasible because: Age &gt;&#xD;
             55 yrs. Unacceptable end organ performance. Patient's refusal.&#xD;
&#xD;
          -  Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months&#xD;
             after standard autotransplant.&#xD;
&#xD;
          -  Male or female; fertile female patients must use a reliable contraception method&#xD;
&#xD;
          -  Age ≤ 75 year old&#xD;
&#xD;
          -  Informed consent given by patient or his/her guardian if of minor age.&#xD;
&#xD;
          -  One or two HLA mismatches with PBSC:&#xD;
&#xD;
               -  One antigenic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
&#xD;
               -  Two allelic mismatches at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
&#xD;
               -  One antigenic mismatch: 1 allelic mismatch at HLA-A or -B or -C or -DRB1 or&#xD;
                  -DQB1.&#xD;
&#xD;
               -  One antigenic mismatch at -DQB1 and one other antigenic mismatch at HLA-A or -B&#xD;
                  or -C or -DRB1&#xD;
&#xD;
               -  Patients with one single allelic mismatch at HLA-A or -B or -C or -DRB1 or -DQB1&#xD;
                  can also be included in the protocol.&#xD;
&#xD;
          -  Hematological malignancies confirmed histologically and not rapidly progressing:&#xD;
&#xD;
               -  AML in complete remission&#xD;
&#xD;
               -  ALL in complete remission&#xD;
&#xD;
               -  CML unresponsive/intolerant to Imatinib but not in blast crisis&#xD;
&#xD;
               -  Other myeloproliferative disorders not in blast crisis and not with extensive&#xD;
                  myelofibrosis&#xD;
&#xD;
               -  MDS with &lt;5% blasts&#xD;
&#xD;
               -  Multiple myeloma not rapidly progressing&#xD;
&#xD;
               -  CLL&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma (aggressive NHL should be chemosensitive)&#xD;
&#xD;
               -  Hodgkin's disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Terminal organ failure, except for renal failure (dialysis acceptable)&#xD;
&#xD;
               -  Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring&#xD;
                  therapy; ejection fraction &lt;35%; uncontrolled arrhythmia; uncontrolled&#xD;
                  hypertension&#xD;
&#xD;
               -  Pulmonary: DLCO &lt; 35% and/or receiving supplementary continuous oxygen&#xD;
&#xD;
               -  Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal&#xD;
                  hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding&#xD;
                  esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic&#xD;
                  dysfunction evinced by prolongation of the prothrombin time, ascites related to&#xD;
                  portal hypertension, bacterial or fungal liver abscess, biliary obstruction,&#xD;
                  chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dL, and symptomatic&#xD;
                  biliary disease&#xD;
&#xD;
          -  Uncontrolled infection, arrhythmia or hypertension&#xD;
&#xD;
          -  Previous radiation therapy precluding the use of 2 Gy TBI&#xD;
&#xD;
          -  10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Baron, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evelyne Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Selleslag, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Brugge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Zachée, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ZNA Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Lewalle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordet Institute, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Bron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bordet Institute, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfried Schroyens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Lechanteur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Etienne Baudoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Maertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KUL, Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rik Schots, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ VUB, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augustin Ferrant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL St. LUC, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucien Noens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZG Gent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Doyen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliiques Universitaire Mont-Godinne, Yvoir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tessa Kerre, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA, Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Graux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires, Mont-Godinne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edeghem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-Luc UCL</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flamish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Flanders Ost</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan</name>
      <address>
        <city>Brugge</city>
        <state>Flanders West</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Stuyvenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU-ULg</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2010</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>HSC transplantation</keyword>
  <keyword>HLA-mismatched</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>GVHD</keyword>
  <keyword>co-infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

